Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Omnitrenidol** is a prescription injection-system kit containing the small-molecule local anesthetic **lidocaine hydrochloride** and the synthetic corticosteroid **triamcinolone acetonide**. Lidocaine blocks voltage-gated sodium-channel-mediated neuronal impulse conduction to produce local or regional anesthesia, while triamcinolone acetonide activates glucocorticoid receptors to suppress inflammatory signaling. The kit is intended for procedural local anesthesia and corticosteroid injection use, including infiltration and nerve-block-related administration routes. The FDA label identifies IT3 Medical as the product packager and lists the product as an abbreviated new drug application product. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e31a76e5-719c-4b4d-8bda-5af71a3e377b))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Omnitrenidol.